Consumer Medicine Information (CMI)
The following information is needed to use ZYKADIA safely and effectively. Remember
to report side effects to your doctor. Your doctor will need to monitor your progress
ZYKADIA can cause serious side effects, including:
Heart problems. ZYKADIA may cause very slow, very fast, or abnormal heartbeats. Your
healthcare provider will carry out blood tests and do an electrocardiogram (ECG) test
periodically during treatment with ZYKADIA. REPORT: new chest pain or discomfort,
changes in heartbeat, palpitations, dizziness, light-headedness, discomfort, fainting,
and changes in or new use of heart or blood pressure medications.
What is in this leaflet
This leaflet answers some common questions about ZYKADIA.
The information in this leaflet was last updated on the date listed on the final page.
More recent information on the medicine may be available.
You should ensure that you speak to your pharmacist or doctor to obtain the most up
to date information on the medicine. You can also download the most up to date leaflet
Those updates may contain important information about the medicine and its use of
which you should be aware.
It does not contain all the available information. It does not take the place of talking
to your doctor or pharmacist.
All medicines have risks and benefits. Your doctor has weighed the risks of you taking
this medicine against the benefits they expect it will provide.
If you have any concerns about this medicine, ask your doctor or pharmacist.
Keep this leaflet with the medicine.
You may need to read it again.
What ZYKADIA is used for
ZYKADIA capsules contain an active substance called ceritinib. ZYKADIA is used to
treat people with non-small cell lung cancer (NSCLC) that is advanced or has spread
to other parts of the body (metastatic) and is caused by a defect in a gene called
ALK (anaplastic lymphoma kinase).
If you have any questions about how ZYKADIA works or why this medicine has been prescribed
for you, ask your doctor or pharmacist.
ZYKADIA is not to be used in children or adolescents under 18 years of age.
This medicine is not addictive.
This medicine is available only with a doctor's prescription.
Before you take ZYKADIA
When you must not take it
Do not take ZYKADIA if you have an allergy to ceritinib, the active ingredient, or
to any of the other ingredients listed at the end of this leaflet.
If you develop these symptoms tell your doctor straight away. They are some of the
signs of an allergic reaction:
difficulty in breathing or swallowing
swelling of the face, lips, tongue or throat
severe itching of the skin, with a red rash or raised bumps
Do not take this medicine after the expiry date printed on the pack or if the packaging
is torn or shows signs of tampering.
In that case, return it to your pharmacist.
Before you start to take it
Take special care with ZYKADIA.
If any of these apply to you, tell your doctor or pharmacist before taking ZYKADIA:
If you have problems with your liver.
If you have problems with your lungs or problems breathing.
If you have problems with your heart, including a condition called long QT syndrome.
If you have diabetes (a high level of sugar in the blood).
If you have/had problems with your pancreas.
If you are currently taking steroids.
If you are pregnant, think you may be pregnant, or plan to become pregnant (see section
If you are breast-feeding or plan to breast-feed (see section Breast-feeding).
Taking other medicines
Tell your doctor or pharmacist if you are taking or have recently taken any other
medicines, including any that you buy without a prescription from your pharmacy, supermarket
or health food shop such as vitamins or herbal supplements, because they might interact
It is particularly important that you mention any of the following medicines:
Medicines used to treat AIDS/HIV such as ritonavir or saquinavir
Medicines used to treat infections. These include medicines which treat fungal infections,
such as antifungals like ketoconazole, itraconazole, voriconazole or posaconazole,
or medicines which treat certain types of bacterial infections, such as antibiotics
Medicines used to treat depression such as nefazodone, or psychosis such as pimozide
St. John's Wort - an herbal product used to treat depression and other conditions,
also known as Hypericum perforatum
Medicines which stop seizures or fits (anti-epileptics such as phenytoin, carbamazepine,
Medicines used to treat tuberculosis such as rifampin or rifabutin
Medicines used to treat irregular heartbeat such as quinidine
Medicines used for increasing motility in the upper gastrointestinal tract such as
Midazolam, a medicine used to treat acute seizures, or as a sedative before or during
surgery or medical procedures
Warfarin, an anticoagulant medicine used to prevent blood clots
Diclofenac, a medicine used to treat joint pain and inflammation
Cyclosporin, tacrolimus and sirolimus, medicines used in organ transplantation to
prevent transplant organ rejection
Dihydroergotamine and ergotamine, medicines used to treat migraine
Alfentanil and fentanyl, medicines used to treat severe pain
Gastric acid-reducing agents (e.g. proton pump inhibitors, H2-receptor antagonists,
Ask your doctor or pharmacist if you are not sure whether your medicine is one of
the medicines listed above.
These medications should be used with care or may need to be avoided during your treatment
If you are taking any of these, your doctor might prescribe an alternative medicine
If you have not told your doctor about any of these things, tell him/her before you
start taking this medicine.
How to take ZYKADIA
Follow all directions given to you by your doctor or pharmacist carefully.
They may differ from the information contained in this leaflet.
Always take ZYKADIA exactly as your doctor has told you. If you do not understand
the instructions on the label, ask your doctor or pharmacist for help.
Do not change the dose without talking to your doctor.
How much to take
The recommended dose of ZYKADIA is 450 mg taken once daily with food (for example
a snack or full meal) at the same time every day. Your doctor will tell you exactly
how many capsules of ZYKADIA you need to take. Do not change the dose without talking
to your doctor.
How to take it
Take ZYKADIA with food.
Swallow ZYKADIA capsules whole with water. Do not chew or crush capsules.
You should not eat grapefruit or drink grapefruit juice during your treatment with
ZYKADIA. It may make the amount of ZYKADIA in your blood increase to a harmful level.
When to take it
Take ZYKADIA once a day at about the same time each day.
If vomiting occurs after you swallow ZYKADIA capsules, do not take any more capsules
until your next scheduled dose.
Do not stop taking ZYKADIA unless your doctor tells you to.
This is a long-term treatment, possibly lasting for months. Your doctor will monitor
your condition to see that the treatment is having the desired effect.
If you have questions about how long to take ZYKADIA, talk to your doctor or pharmacist.
If you forget to take it
If you forget to take ZYKADIA, do not take the missed dose; just take your next dose
at the regular time. Do not take a double dose of ZYKADIA to make up for the dose
If you have any further questions on the use of this medicine, ask your doctor or
If you have trouble remembering to take your medicine, ask your pharmacist for some
If you take too much (overdose)
Immediately telephone your doctor or the Poisons Information Centre (telephone 13
11 26) for advice, or go to Accident and Emergency at the nearest hospital (take the
pack with you) if you think that you or anyone else may have taken too much ZYKADIA.
Do this even if there are no signs of discomfort or poisoning. Keep the telephone
While you are taking ZYKADIA
Things you must do
Tell your doctor or pharmacist immediately if you get any of these symptoms during
treatment with ZYKADIA:
If you experience tiredness, itchy skin, yellow skin or the whites of your eyes turn
yellow, nausea or vomiting, decreased appetite, pain on the right side of your stomach,
dark or brown urine, or you bleed or bruise more easily than normal because these
may be signs of liver problems.
If you experience new or worsening symptoms such as cough with or without mucous,
fever, chest pain, trouble breathing or shortness of breath because these may be signs
of lung problems.
If you experience chest pain or discomfort, changes in your heartbeat (fast or slow),
light-headedness, fainting, dizziness, blue discoloration of your lips, shortness
of breath, or swelling of your lower limbs (oedema) or skin because these may be signs
of heart problems.
If you experience diarrhoea, nausea or vomiting because they may be signs of gastrointestinal
If you experience excessive thirst or increased frequency of urination because they
may be signs of a high level of sugar in the blood.
Your doctor may need to adjust, temporarily stop or completely discontinue your treatment
Keep all of your doctor's APPOINTMENTS so that your progress can be checked.
Your doctor should do blood tests before you start treatment with ZYKADIA to check
your liver and pancreas and to check the level of sugar in your blood. Your doctor
should do blood tests every month thereafter to check your liver while you are taking
ZYKADIA. Your doctor should also do blood tests to check your pancreas and the level
of sugar in your blood regularly while you are taking ZYKADIA.
WOMEN OF CHILD BEARING AGE
You must use a highly effective method of birth control during treatment with ZYKADIA
and for 3 months after stopping ZYKADIA. ZYKADIA may decrease the effectiveness of
the oral contraceptive.
Your doctor will discuss with you the optimal birth control (contraceptive) method
for you to use during treatment with ZYKADIA.
PREGNANCY AND BREAST-FEEDING
ZYKADIA should not be used during pregnancy, unless the potential benefit to the patient
outweigh the potential risk to the foetus.
If you are pregnant or think you might be pregnant or plan to become pregnant, ask
your doctor for advice.
Your doctor will discuss with you the potential risks of taking ZYKADIA during pregnancy.
ZYKADIA should not be used during breast-feeding.
You and your doctor will decide together whether you should breast-feed or take ZYKADIA.
YOU SHOULD NOT DO BOTH.
Tell your doctor straight away if you become pregnant while taking this medicine.
If you are about to be started on any new medicine, remind your doctor and pharmacist
that you are taking this medicine.
Tell any other doctors, dentists, and pharmacists who treat you that you are taking
Things you must not do
This medicine has been prescribed for you only. Do not use it for any other complaints
unless your doctor tells you to.
Do not give this medicine to anyone else, even if their condition seems similar to
yours. It may harm them.
Things to be careful of
Be careful driving, operating machinery or doing jobs that require you to be alert
until you know how ZYKADIA affects you.
Tell your doctor or pharmacist as soon as possible if you notice any side effects
not listed in this leaflet.
As with all medicines, patients treated with ZYKADIA may experience side effects,
although not everybody gets them.
STOP taking ZYKADIA and seek medical help immediately if you experience any of the
following, which may be signs of an allergic reaction:
difficulty in breathing or swallowing
swelling of the face, lips, tongue or throat
severe itching of the skin, with a red rash or raised bumps
Tell your doctor or pharmacist IMMEDIATELY if you experience any of the following
SERIOUS SIDE EFFECTS. You may need medical treatment.
Irregular or slow heartbeat
Pain in the chest
Cough, difficult or painful breathing, wheezing, pain in chest when breathing in,
Yellow skin and eyes, nausea, loss of appetite, dark urine
Severe upper stomach pain resulting from inflammation of the pancreas
The following list includes OTHER SIDE EFFECTS of your medicine. If they BECOME SEVERE,
please tell your doctor, pharmacist or healthcare provider.
VERY COMMON SIDE EFFECTS
COMMON SIDE EFFECTS
Excessive thirst, high urine flow, increased appetite with weight loss
Significantly decreased urine flow
Some people may have other side effects not yet known or mentioned in this leaflet.
If you notice any side effects not listed in this leaflet, please inform your doctor
Some side effects, for example, changes in kidney and liver function or abnormal blood
test results (high levels of pancreatic enzymes called lipase and amylase in the blood),
can only be found when your doctor does tests from time to time to check your progress.
After using ZYKADIA
Keep your medicine in the original package until it is time to take it.
Store it in a cool, dry place, below 30°C
Do not store this medicine or any other medicine in the bathroom or near a sink
Do not leave it in the car or on window sills.
Keep the medicine where children cannot reach it.
A locked cupboard at least one-and-a-half metres above the ground is a good place
to store medicines.
If your doctor tells you to stop taking this medicine or the expiry date has passed,
ask your pharmacist what to do with any medicine you have left over.
What it looks like
ZYKADIA hard capsules are opaque white and blue. The opaque blue cap is marked with
black ink "LDK 150MG" and the opaque white body is marked with black ink "NVR". The
capsule contains a white to almost white powder. One blister strip contains 10 hard
capsules. Multipacks contain 150 (3 packs of 50) hard capsules.
ZYKADIA hard capsules contain 150 mg of the active ingredient ceritinib.
Excipients with known effect: contains sulfites.
The inactive capsule contents are: microcrystalline cellulose, hyprolose, sodium starch
glycolate type A, magnesium stearate, colloidal anhydrous silica.
The hard capsule colouring agents are titanium dioxide, indigo carmine.
The printing ink used to mark the capsule is OPACODE monogramming ink S-1-277002 BLACK.
ZYKADIA® is supplied in Australia by:
NOVARTIS Pharmaceuticals Australia Pty Limited
ABN 18 004 244 160
54 Waterloo Road
Macquarie Park NSW 2113
Telephone 1 800 671 203
Web site: www.novartis.com.au
®= Registered Trademark
This leaflet was prepared on
16 June 2020
Australian Registration Number.
AUST R 235737
Internal Document Code:
(zyk160620c.doc) based on PI (zyk160620i.doc)